Crews Bank & Trust’s Acrivon Therapeutics ACRV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-1,044
Closed -$1.86K – 221
2026
Q2
$1.86K Buy
+1,044
New +$1.77K ﹤0.01% 637

Other funds holding ACRV

Crews Bank & Trust's ACRV Position: Q3 2026 in Review

Crews Bank & Trust sold out of Acrivon Therapeutics (ACRV) in Q3 2026, closing a stake of 1,044 shares — an estimated $1.86K sold.

Crews Bank & Trust first reported a position in ACRV in Q2 2026 and held it in 1 quarter. The position peaked at $1.86K in Q2 2026. 47 funds tracked by Wall St. Rank hold ACRV as of Q3 2026.

  • Crews Bank & Trust reported no remaining Acrivon Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Crews Bank & Trust sold 1,044 Acrivon Therapeutics shares in Q3 2026, an estimated $1.86K.
  • Crews Bank & Trust first reported a position in Acrivon Therapeutics in Q2 2026 and held it in 1 quarter.
  • Crews Bank & Trust's Acrivon Therapeutics position peaked at $1.86K in Q2 2026.
  • 47 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q3 2026.

Based on Crews Bank & Trust's 13F filing for Q3 2026, filed 16 Nov 2026.